Patents Examined by Claire Kaufman
-
Patent number: 11787867Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.Type: GrantFiled: March 5, 2021Date of Patent: October 17, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Robert Babb, Drew Dudgeon, Yu Huang, Rosalynn Molden, William Olson, Matthew Sleeman, Dimitris Skokos, Bei Wang
-
Patent number: 11767364Abstract: Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.Type: GrantFiled: March 1, 2021Date of Patent: September 26, 2023Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Mukundrao Pashine, Guodong Chen
-
Patent number: 11766454Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.Type: GrantFiled: August 19, 2020Date of Patent: September 26, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Irving L. Weissman, Mingye Feng, Jens-Peter Volkmer
-
Patent number: 11746148Abstract: The present invention provides an artificially designed antibody molecule comprising four polypeptide chains, where each of the first polypeptide chain and the third polypeptide chain comprises an immunoglobulin light chain, and each of the second polypeptide chain and the fourth polypeptide chain comprises, from the N-terminus to the C-terminus, an immunoglobulin heavy chain variable region, an immunoglobulin CH1 domain, a VHH, an immunoglobulin CH2 domain, an immunoglobulin CH3 domain, and optionally an immunoglobulin CH4 domain. The present invention also provides a polynucleotide encoding the antibody molecule, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate and a pharmaceutical composition comprising the antibody molecule, and use of the antibody molecule in the immunotherapy, prevention and/or diagnosis of diseases.Type: GrantFiled: March 26, 2019Date of Patent: September 5, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Junjian Liu, Xiaoniu Miao, Zhihui Kuang
-
Patent number: 11732044Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.Type: GrantFiled: December 27, 2018Date of Patent: August 22, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoniu Miao, Huajing Hu, Andy Tsun, Junjian Liu, Xiaolin Liu
-
Patent number: 11725053Abstract: The present invention is directed to a chimeric antigen receptor fusion protein comprising: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the CAR further comprises a human transferrin fragment, which is an epitope for an antibody against human transferrin, at N-terminus or C-terminus to scFv, or between VH and VL. Preferred tumor antigens are CD19, CD22 and BCMA. The CD19-TF-CAR-T cells, CD22-TF-CAR-T cells, and BAMA-TF CAR-T cells secrete less cytokines, but they have the same efficacy against cancer target cells when comparing with same CAR without TF.Type: GrantFiled: June 18, 2020Date of Patent: August 15, 2023Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., LtdInventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 11725058Abstract: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.Type: GrantFiled: June 24, 2020Date of Patent: August 15, 2023Assignee: AP Biosciences, Inc.Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Jeng-Horng Her
-
Patent number: 11718672Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.Type: GrantFiled: February 14, 2022Date of Patent: August 8, 2023Assignee: Chugai Seiyaki Kabushiki KaishaInventors: Sotaro Naoi, Shu Feng, Tomoyuki Igawa, Shu Wen Samantha Ho
-
Patent number: 11718679Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.Type: GrantFiled: October 31, 2018Date of Patent: August 8, 2023Assignee: Compass Therapeutics LLCInventors: Ugur Eskiocak, Robert V. Tighe, III
-
Patent number: 11718669Abstract: The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.Type: GrantFiled: August 10, 2022Date of Patent: August 8, 2023Assignee: AGENUS INC.Inventors: Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
-
Patent number: 11701387Abstract: The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).Type: GrantFiled: January 4, 2019Date of Patent: July 18, 2023Inventors: Rafijul Bari, Markus Granzin, Wing Leung, Andrzej Dzionek, Martin Meyer
-
Patent number: 11702478Abstract: The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.Type: GrantFiled: September 19, 2018Date of Patent: July 18, 2023Assignee: MAB DISCOVERY GMBHInventors: Stephan Fischer, Karsten Beckmann
-
Patent number: 11685786Abstract: The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.Type: GrantFiled: September 22, 2017Date of Patent: June 27, 2023Assignee: MERUS N.V.Inventors: Cecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
-
Patent number: 11673963Abstract: Disclosed herein are antibodies directed against CRTAM, nucleic acids encoding such antibodies, host cells comprising such nucleic acids encoding the antibody, methods for preparing anti-CRTAM antibodies, and methods for the treatment of diseases, e.g., human cancers, including but not limited to small cell lung cancer, non-small cell lung cancer (including squamous carcinomas and adenocarcinomas) skin cancer including melanoma, breast cancer (including TNBC), colorectal cancer, gastric cancer, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, liver cancer including hepatocellular carcinoma, pancreatic cancer, head and neck cancer, nasopharyngeal cancer, oesophageal cancer, bladder cancer and other uroepithelial cancers, stomach cancer, glioma, glioblastoma, testicular, thyroid, bone, gallbladder and bile ducts, uterine, adrenal cancers, sarcomas, GIST, neuroendocrine tumours, and haematological malignancies.Type: GrantFiled: November 1, 2018Date of Patent: June 13, 2023Assignee: Oxford BioTherapeutics LtdInventors: Arnima Bisht, Rachel L. Dusek, Haining Huang, Chuck Hannum, James Edward Ackroyd, Livija Deban
-
Patent number: 11662339Abstract: The present invention provides markers for judging the efficacy of therapy with a PD-1 signal inhibitor before or at an early stage of the therapy. As biomarkers for predicting or judging the efficacy of therapy with a PD-1 signal inhibitor, surrogate indicators of metabolic changes relating to mitochondrial activity in T cells and/or T cell activation in a subject are used. As such indicators, intestinal flora-related metabolites in the serum or plasma, energy metabolism-related metabolites in the serum or plasma, amino acid metabolism-related metabolites and/or derivatives thereof in the serum of plasma, oxygen consumption rate and/or ATP turnover in peripheral blood CD8+ cells, amino acids in T cells, and T-bet in peripheral blood CD8+ cells may be used.Type: GrantFiled: November 1, 2017Date of Patent: May 30, 2023Assignee: Kyoto UniversityInventors: Tasuku Honjo, Kenji Chamoto, Fumihiko Matsuda, Yasushi Okuno, Sidonia Fagarasan
-
Patent number: 11643470Abstract: Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.Type: GrantFiled: May 11, 2020Date of Patent: May 9, 2023Assignee: AP Biosciences, Inc.Inventors: Jhong-Jhe You, Ching-Hsuan Hsu, Po-Lin Huang, Hung-Tsai Kan, Ting-Yi Chang, Hsin-Ta Hsieh, Jeng-Horng Her
-
Patent number: 11633399Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.Type: GrantFiled: January 8, 2020Date of Patent: April 25, 2023Assignee: Sol-Gel Technologies Ltd.Inventors: Moshe Arkin, Marcel Zighelboim, Ori Nov, Ofer Toledano, Karine Neimann
-
Patent number: 11603404Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.Type: GrantFiled: May 2, 2022Date of Patent: March 14, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
-
Patent number: 11590202Abstract: The present invention provides compositions and methods for selective inhibition of the classical or non-classical LT?R-NF?B signaling pathway. In some embodiments, the compositions and methods of the present invention are useful for treating or preventing tissue graft rejection, inflammation, contact hypersensitivity, and cancer by decreasing cell motility.Type: GrantFiled: April 11, 2018Date of Patent: February 28, 2023Assignee: University of Maryland, BaltimoreInventors: Jonathan Bromberg, Wenji Piao, Yanbao Xiong
-
Patent number: 11578129Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.Type: GrantFiled: March 26, 2020Date of Patent: February 14, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Vittoria Zinzalla, Markus Johann Bauer, Barbara Drobits-Handl